http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Red Cell Distribution Width: A Novel Marker of Activity in Infl ammatory Bowel Disease
Atakan Yeşil,Ebubekir Şenateş,İbrahim Vedat Bayoğlu,Emrullah Düzgün Erdem,Refi k Demirtunç,Ayşe Oya Kurdaş Övünç 거트앤리버 소화기연관학회협의회 2011 Gut and Liver Vol.5 No.4
Background/Aims: Studies concerning red cell distribution width (RDW) for use in the assessment of infl ammatory bowel disease (IBD) activity are limited. We investigated whether RDW is a marker of active disease in patients with IBD. Methods: In total, 61 patients with ulcerative colitis (UC)and 56 patients with Crohn’s disease (CD) were enrolled in the study group, and 44 age- and-sex-matched healthy volunteers were included as the control group. A CD activity index >150 in patients with CD indicated active disease. Patients with moderate and severe disease based on the Truelove-Witts criteria were considered to have active UC. In addition to RDW, serum C-reactive protein levels, erythrocyte sedimentation rates, and platelet counts were measured. Results: Twenty-nine (51.7%) patients with CD and 35 (57.4%)patients with UC had active disease. The RDW was significantly higher in patients with CD and UC than in controls (p<0.001 and p<0.001, respectively). A subgroup analysis indicated that for a RDW cut-off of 14%, the sensitivity for detecting active CD was 79%, and the specicity was 93% (area under curve [AUC], 0.935; p<0.001). RDW was the most sensitive and specifi c marker for active CD. However, it was not valid for UC, as the ESR at a cutoff of 15.5 mm/hr showed a sensitivity of 83% and a specicity of 76% (AUC, 0.817;p<0.001), whereas the RDW at a cutoff of 14% showed 17%sensitivity and 84% specicity for detecting active UC. Conclusions:RDW was elevated in IBD in comparison with healthy controls and increased markedly in active disease. RDW may be a sensitive and specifi c marker for determining active CD,whereas ESR is an important marker of active UC.
Mesut Sezikli,Züleyha Akkan Çetinkaya,Fatih Güzelbulut,Atakan Yeşil,Mustafa Erhan Altınöz,Nuriye Ulu,Ayşe Oya Övünç Kurdaş 거트앤리버 소화기연관학회협의회 2012 Gut and Liver Vol.6 No.1
Background/Aims: The aim of this study was to evaluate the eradication rate of a triple therapy regimen that included a proton pump inhibitor, amoxicillin, and tetracycline instead of clarithromycin in treatment-naïve patients and in patients who did not respond to standard triple therapy. Methods: This study included 110 patients infected with Helicobacter pylori. Patients in groups A and B were treatment-naïve, and those in group C were not responsive to previous standard triple therapy. Patients in group A (n=40) received lansoprazole 30 mg b.i.d., amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d. for 14 days. Patients in groups B (n=40) and C (n=30) received lansoprazole 30 mg b.i.d., amoxicillin 1,000 mg b.i.d., and tetracycline 500 mg q.i.d. for 14 days. Results: In group A, eradication was achieved in 18 (45%) of the 40 patients included in the intention-to-treat (ITT) analysis and in 18 (47.4%) of the 38 patients included in the per-protocol (PP) analysis. In group B, eradication was achieved in 15 (37.5%) of the 40 patients included in the ITT analysis and in 15 (39.3%) of the 38 patients included in the PP analysis. In group C, eradication was achieved in 14 (46.6%) of the 30 patients included in the ITT analysis and in 14 (43.8%) of the 29 patients included in the PP analysis. There was no statistically signifi cant difference among the 3 groups with regard to eradication rates (p>0.05). Conclusions: Despite the low rate of resistance to tetracycline, the combination of lansoprazole, amoxicillin, and tetracycline instead of clarithromycin is not a good option for the eradication of H. pylori.